Transcription factor Nrf2 can mediate TMZ resistance via the synthesis and utilization of GSH, and inhibition of Nrf2 increases the TMZ sensitivity of glioma cells (169, 170). The gene discussed is NFE2L2; the disease is central nervous system cancer.